Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Celestino Menchavez

Pediatrics Cumberland, MD Medical Doctor

NPI 1144373549 CMS profile 737801

915 Bishop Walsh Rd, Cumberland, MD 21502

Open in the dashboard

General payments

$3,101

137 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Celestino Menchavez of Cumberland, MD is reported in the CMS Open Payments database as having received $3,101 across 137 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $529 29
2024 General $733 16
2023 General $432 19
2022 General $419 21
2021 General $457 22
2020 General $205 11
2019 General $325 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Celestino Menchavez
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Celestino Menchavez were reported at $529. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Celestino Menchavez Pediatrics median Middle half National median
2019 $325 $86 $31–$183 $163
2020 $205 $49 $22–$110 $114
2021 $457 $68 $27–$158 $132
2022 $419 $77 $30–$173 $149
2023 $432 $88 $33–$190 $160
2024 $733 $94 $34–$206 $164
2025 $529 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Supernus Pharmaceuticals, Inc. $739 19 payments
  2. Ironshore Pharmaceuticals Inc. $452 21 payments
  3. Merck Sharp & Dohme Corporation $297 14 payments
  4. Pfizer Inc. $282 15 payments
  5. GlaxoSmithKline, LLC. $245 12 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $222 12 payments
  7. Corium, Inc. $189 9 payments
  8. Collegium Pharmaceutical, Inc. $148 10 payments
  9. Sanofi Pasteur Inc. $121 6 payments
  10. ARS Pharmaceuticals Operations, Inc. $115 6 payments
  11. Other $291 13 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,101 137 payments
Products named General payments · program years 2019–2025
  1. Qelbree Viloxazine Hydrochloride $428 4 payments
  2. QELBREE Psychology $311 15 payments
  3. GARDASIL 9 $285 13 payments
  4. JORNAY PM Central Nervous Stimulant ADHD $229 11 payments
  5. VAXNEUVANCE $213 9 payments
  6. VAXELIS $210 9 payments
  7. EUCRISA $193 9 payments
  8. Azstarys $189 9 payments
  9. JORNAY PM Central Nervous System Stimulant $184 8 payments
  10. BEXSERO $159 8 payments
  11. Other $2,095 108 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

137 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record